UBS Group’s Cocrystal Pharma COCP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.34K | Sell |
4,133
-511
| -11% | -$629 | ﹤0.01% | 9063 |
|
|
2026
Q1 | $4.69K | Buy |
4,644
+2,867
| +161% | +$2.96K | ﹤0.01% | 8897 |
|
|
2025
Q4 | $1.74K | Buy |
1,777
+1,206
| +211% | +$1.28K | ﹤0.01% | 9482 |
|
|
2025
Q3 | $714 | Sell |
571
-21,344
| -97% | -$32.9K | ﹤0.01% | 9557 |
|
|
2025
Q2 | $32.7K | Buy |
21,915
+5,109
| +30% | +$7.61K | ﹤0.01% | 8102 |
|
|
2025
Q1 | $23.9K | Buy |
16,806
+10,676
| +174% | +$19.9K | ﹤0.01% | 8108 |
|
|
2024
Q4 | $12.4K | Buy |
6,130
+5,220
| +574% | +$10.4K | ﹤0.01% | 8196 |
|
|
2024
Q3 | $1.6K | Buy |
+910
| New | +$1.77K | ﹤0.01% | 8597 |
|
|
2024
Q2 | – | Sell |
-20,258
| Closed | -$28.4K | – | 9588 |
|
|
2024
Q1 | $28.4K | Buy |
20,258
+20,091
| +12,031% | +$31.3K | ﹤0.01% | 6762 |
|
|
2023
Q4 | $288 | Buy |
+167
| New | +$297 | ﹤0.01% | 8746 |
|
|
2023
Q3 | – | Sell |
-276
| Closed | -$660 | – | 9524 |
|
|
2023
Q2 | $660 | Sell |
276
-1,716
| -86% | -$4.17K | ﹤0.01% | 8147 |
|
|
2023
Q1 | $3.96K | Sell |
1,992
-3,023
| -60% | -$6.75K | ﹤0.01% | 8249 |
|
|
2022
Q4 | $9.78K | Buy |
5,015
+4,550
| +978% | +$11.7K | ﹤0.01% | 8610 |
|
|
2022
Q3 | $2K | Buy |
465
+348
| +297% | +$1.63K | ﹤0.01% | 9702 |
|
|
2022
Q2 | $1K | Sell |
117
-1,398
| -92% | -$7.45K | ﹤0.01% | 9837 |
|
|
2022
Q1 | $10K | Sell |
1,515
-1,424
| -48% | -$9.47K | ﹤0.01% | 8401 |
|
|
2021
Q4 | $23K | Buy |
2,939
+1,939
| +194% | +$19.8K | ﹤0.01% | 7673 |
|
|
2021
Q3 | $13K | Buy |
1,000
+149
| +18% | +$1.97K | ﹤0.01% | 7655 |
|
|
2021
Q2 | $13K | Buy |
851
+344
| +68% | +$5.23K | ﹤0.01% | 7772 |
|
|
2021
Q1 | $8K | Buy |
+507
| New | +$10.3K | ﹤0.01% | 8077 |
|
|
2020
Q4 | – | Sell |
-29
| Closed | – | – | 8423 |
|
|
2020
Q3 | $0 | Sell |
29
-1,416
| -98% | -$25.8K | ﹤0.01% | 8032 |
|
|
2020
Q2 | $26K | Buy |
1,445
+512
| +55% | +$6.27K | ﹤0.01% | 6370 |
|
|
2020
Q1 | $8K | Buy |
933
+925
| +11,563% | +$8.71K | ﹤0.01% | 7069 |
|
|
2019
Q4 | $0 | Buy |
+8
| New | +$80 | ﹤0.01% | 8135 |
|
|
2019
Q3 | – | Sell |
-32
| Closed | -$1K | – | 8023 |
|
|
2019
Q2 | $1K | Sell |
32
-126
| -80% | -$3.74K | ﹤0.01% | 7702 |
|
|
2019
Q1 | $5K | Buy |
+158
| New | +$5.78K | ﹤0.01% | 7151 |
|
|
2018
Q4 | – | Sell |
-344
| Closed | -$10K | – | 8056 |
|
|
2018
Q3 | $10K | Buy |
+344
| New | +$15.4K | ﹤0.01% | 7158 |
|
|
2018
Q2 | – | Sell |
-217
| Closed | -$15K | – | 8009 |
|
|
2018
Q1 | $15K | Buy |
+217
| New | +$13.5K | ﹤0.01% | 6610 |
|
Other funds holding COCP
VCM
VFT
PA
GSC
UBS Group's COCP Position: Q2 2026 in Review
UBS Group reduced its Cocrystal Pharma (COCP) stake by 11% in Q2 2026, selling an estimated $629 and leaving 4,133 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #9063.
UBS Group first reported a position in COCP in Q1 2018 and has held it in 28 quarters since. The position peaked at $32.7K in Q2 2025. 19 funds tracked by Wall St. Rank hold COCP as of Q2 2026.
- UBS Group held 4,133 shares of Cocrystal Pharma worth $4.34K as of Q2 2026.
- UBS Group sold 511 Cocrystal Pharma shares in Q2 2026, an estimated $629.
- Cocrystal Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9063 holding.
- UBS Group first reported a position in Cocrystal Pharma in Q1 2018 and has held it in 28 quarters since.
- UBS Group's Cocrystal Pharma position peaked at $32.7K in Q2 2025.
- 19 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.